1. WHAT IS PAPIG?

2. WHAT IS PAPIG?  A sub group of SMC

3. WHAT IS PAPIG?  A sub group of SMC  Members include: 3 Public Partners 1 member of SMC 1 member of ABPI 1 member of NHS Scotland

4. WHAT DO WE DO?

5.  Promote public awareness and involvement in SMC WHAT DO WE DO?

6.  Promote public awareness and involvement in SMC WHAT DO WE DO?  Public Partners provide a summary of the Patient and Carer’s perspective when this has been provided as a Patient Interest Group submission

7. PATIENT INVOLVEMENT

8. PATIENT INVOLVEMENT  Involvement of patients in the decision making process is key - PAPIG’s role is to ensure that the views, needs and issues of patients are put before SMC for consideration as part of the process of evaluation of new medicines.

9. OBJECTIVES FOR THE DAY

10. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.

11. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland

12. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members

13. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.

14. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.  Understand what is needed to make a Patient Interest Group submission to SMC

15. OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.  Understand what is needed to make a Patient Interest Group submission to SMC  A chance to ask questions, share ideas and exchange feedback with fellow delegates and today’s presenters.

16. SUMMARY A good submission will tell SMC:

17. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available

18. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines

19. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer

20. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences

21. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have

22. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have  The submission is concise, specific and focussed

23. SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have  The submission is concise, specific and focussed  Makes clear any declarations of interest